Eli Lilly Aktie

855,20 EUR -1,20 EUR -0,14 %

20:26:42

FSE

928,13 USD +16,74 USD +1,84 %

21:41:27

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.807,70 Mrd. EUR

KGV65,91Div. Rendite0,67%

WKN858560

ISINUS5324571083

SymbolLLY

Eli Lilly Aktien News

Sortieren:Datum Meistgelesen

27.06.22PR NewswireLilly Declares Third-Quarter 2022 Dividend

27.06.22RSSStatement of changes in beneficial ownership of securities

24.06.22RSSStatement of changes in beneficial ownership of securities

23.06.22RSSStatement of changes in beneficial ownership of securities

14.06.22PR NewswireFDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata

10.06.22MyDividendsEli Lilly zahlt Dividende für das zweite Quartal aus

07.06.22PR NewswireEight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials

07.06.22PR NewswireNew analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®

05.06.22PR NewswireJardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world eviden...

04.06.22PR NewswireLilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight

03.06.22PR NewswireLilly to Participate in Goldman Sachs Global Healthcare Conference

31.05.22RSSStatement of changes in beneficial ownership of securities

26.05.22PR NewswireLilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

25.05.22PR NewswireLilly plans to invest $2.1 billion in new manufacturing sites in Indiana

25.05.22RSSStatement of changes in beneficial ownership of securities

24.05.22PR NewswireFifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study

23.05.22PR NewswireLilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA

20.05.22PR NewswireCHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)

19.05.22RSSStatement of changes in beneficial ownership of securities

18.05.22RSSStatement of changes in beneficial ownership of securities

17.05.22RSSStatement of changes in beneficial ownership of securities

16.05.22PR NewswireLilly to Participate in UBS Global Healthcare Conference 2022

13.05.22PR NewswireFDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes

11.05.22PR NewswireFDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

06.05.22PR NewswireMary Lynne Hedley Elected to Lilly Board of Directors

03.05.22PR NewswireLilly to Participate in Bank of America Securities 2022 Healthcare Conference

03.05.22MyDividendsEli Lilly meldet Dividende für das zweite Quartal

02.05.22PR NewswireLilly Declares Second-Quarter 2022 Dividend

28.04.22PR NewswireSolid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022

28.04.22PR NewswireLilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1

19.04.22PR NewswireLilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement

19.04.22RSSForm 4 59478

11.04.22PR NewswireLilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

07.04.22RSSForm 4 59478

01.04.22PR NewswireLilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress

29.03.22RSSForm 4 59478

28.03.22PR NewswireInnovent and Lilly Expand Strategic Partnership in Oncology

26.03.22PR NewswireNearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies

26.03.22PR NewswireMajority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.